CVRX
The market loved the numbers. Then it met the forecast.
CVRx turned in a pretty decent second quarter: revenue rose 16% to $15.7 million, gross margin improved to 87%, and the company narrowed its loss a bit. On paper, that’s the kind of report that can keep a small-cap medtech name humming along.
Then came the part investors hate
The problem was the 2026 outlook. CVRx cut full-year revenue guidance to $58 million to $60 million and guided third-quarter revenue to $13.5 million to $14.5 million. Translation: the business is still growing, but not as fast as management thought a few months ago. The stock’s overnight plunge shows which line item mattered more.
Management blamed a few not-so-fun culprits:
- fewer sales territories than expected
- lower sales force productivity
- a longer-than-expected problem with one of its biggest payers
That’s a classic Wall Street plot twist: the quarter looks fine, but the path forward gets foggier.
Why Humana shows up in the story
CVRx also pointed to a new Medicare Advantage coverage policy from Humana for Barostim, effective in May, as a reimbursement win. That’s helpful for the long-term setup, but it wasn’t enough to offset the near-term guidance haircut.
Big picture: CVRx is still growing its implant base and improving margins, but the market is clearly saying, “Cool story — now show me the second half.”